VDR rs11568825: Calcium Absorption & Bone Health
The rs11568825 single nucleotide polymorphism is a regulatory variant located in the promoter region of the vitamin D receptor (VDR) gene. It alters the binding affinity of the intestine-specific transcription factor Cdx2, modulating the transcriptional activity of VDR. In scientific literature, this variant has been studied for its modest associations with intestinal calcium absorption efficiency and long-term osteoporosis susceptibility.
What each genotype means
Higher transcription factor binding
This genotype is associated with increased binding of the Cdx2 transcription factor to the vitamin D receptor gene promoter. Research suggests this may influence the efficiency of intestinal calcium absorption and bone mineral density, though findings remain limited and vary across different populations.
This genotype is less common globally, with frequencies varying significantly by ancestry.
Intermediate transcription factor binding
Carriers of this genotype possess one copy of each allele, resulting in intermediate binding activity of the Cdx2 transcription factor. Some studies have observed an increased risk of lower bone mineral density in the lumbar spine for individuals with this genotype, particularly in Caucasian populations, though evidence is not consistent across all groups.
This is a common genotype found in many populations, with higher prevalence in East Asian groups.
Lower transcription factor binding
This genotype is associated with reduced binding of the Cdx2 transcription factor compared to the A allele. While this variant is linked to potential differences in calcium absorption efficiency and osteoporosis susceptibility, the clinical impact is considered limited and depends on a complex interplay of environmental and genetic factors.
This is the most frequent genotype in many global populations, particularly in East Asian ancestry groups.
Genetic Architecture and Molecular Mechanism
The single nucleotide polymorphism rs11568825, widely known in medical literature as the VDR Cdx-2 or Cdx2 promoter polymorphism, resides on chromosome 12 within the 5-prime upstream promoter region of the human vitamin D receptor gene. Rather than modifying the amino acid sequence of the receptor itself, this single base substitution (involving guanine and adenine alleles) is positioned directly within a recognition sequence for caudal-type homeobox transcription factor 2 (Cdx2). Cdx2 is an essential intestine-specific transcription factor that directs the expression of genes involved in mucosal differentiation and nutrient transport. In functional laboratory assays, the A allele creates a higher-affinity binding site for Cdx2 compared to the G allele. This enhanced binding stimulates higher baseline transcriptional activity of the VDR gene promoter in intestinal epithelial cells, facilitating greater downstream transcription of the receptor.
The Biological Role of the Vitamin D Receptor
The VDR gene encodes the vitamin D receptor, a nuclear hormone receptor superfamily member that functions as an intracellular transcription factor. Upon binding its biologically active ligand, 1,25-dihydroxyvitamin D3 (calcitriol), VDR forms a heterodimer with the retinoid X receptor (RXR). This molecular complex binds to vitamin D response elements across the genome to initiate transcription of various target genes. A primary physiological function of VDR is orchestrating systemic mineral homeostasis. In the duodenum and jejunum, activated VDR drives the expression of epithelial calcium channels, intracellular calbindin proteins, and basolateral calcium pumps, which together power active transcellular calcium absorption. While high-penetrance coding mutations in VDR lead to severe rare monogenic diseases like vitamin D-dependent rickets type 2A, common regulatory variants like rs11568825 subtly modulate how sensitive intestinal tissue is to ambient vitamin D.
Evidence on Bone Density and Osteoporosis Susceptibility
Because the A allele enhances Cdx2-mediated VDR promoter activation, research groups initially hypothesized that individuals carrying the A allele would exhibit enhanced intestinal calcium absorption and improved bone mineral density (BMD). Early candidate gene studies demonstrated that the A allele was statistically associated with higher lumbar spine bone density and reduced rates of osteoporotic fractures compared to the G allele. However, cumulative evidence over decades of bone genetics research reveals that the strength of this association is modest and somewhat inconsistent. Large-scale genome-wide association studies (GWAS) and meta-analyses have shown that common skeletal traits and fracture risks are highly polygenic, influenced by thousands of variants with subtle effect sizes. While rs11568825 demonstrates clear molecular effects in vitro, its real-world impact on clinical bone disease risk remains limited and heavily influenced by dietary calcium intake and systemic vitamin D sufficiency.
Population Frequency and Diversity
Allele frequencies for rs11568825 display notable divergence across global ancestral groups. According to aggregate population genomic databases and published anthropological cohorts, the minor allele frequency globally averages approximately 0.18. The ancestral G allele is the predominant form across many European-descent and African-descent populations. In contrast, the functional A allele occurs with significantly higher frequency in East Asian populations, where minor allele frequencies often reach 0.38 or higher. Because background linkage disequilibrium patterns and dietary traditions differ substantially across geographic regions, the clinical correlations observed for rs11568825 in one ancestral population cannot be automatically generalized to others without direct epidemiological validation.
What This Information Means for You
Discovering your rs11568825 genotype through commercial or research sequencing provides educational insight into personal biology, but it cannot diagnose any medical condition. Having one or two copies of the lower-activity G allele does not mean you will develop osteoporosis, nor does carrying the A allele guarantee lifelong bone resilience. Skeletal health is an integrative physiological outcome driven by age, sex, hormonal status, physical activity, and nutritional adequacy. This genetic result should never be used as a standalone indicator to begin high-dose vitamin D or calcium supplementation, as excess intake can introduce separate health risks such as kidney stones. If you have personal concerns about bone density, fracture risks, or nutritional needs, consult a licensed healthcare professional for clinical evaluation, such as serum 25-hydroxyvitamin D testing or dual-energy X-ray absorptiometry (DEXA) screening.
How common is this variant?
The minor A allele has a global frequency of approximately 0.18, but its prevalence varies by ancestry, reaching roughly 0.38 in East Asian populations while remaining less common in European cohorts.
Frequently asked questions
Can rs11568825 determine if I have osteoporosis?
No. The rs11568825 variant is not a diagnostic test for osteoporosis or fracture risk. Osteoporosis is a complex condition influenced by thousands of subtle genetic markers alongside lifestyle, age, hormonal factors, and nutrition.
Should I take extra calcium or vitamin D if I have the GG genotype?
You should not start high-dose dietary supplements solely based on your genetic test results. Calcium and vitamin D supplementation should be guided by your primary care physician, who can measure serum vitamin D levels and assess your actual dietary intake.
Why is this variant called the Cdx-2 polymorphism?
It is named Cdx-2 because the single nucleotide change is located inside the promoter sequence where the caudal-type homeobox transcription factor 2 (Cdx2) attaches. The change alters how tightly this regulatory factor binds to the VDR promoter.
Is the A allele always protective against bone loss?
Not necessarily. Although laboratory assays and several candidate studies link the A allele to higher intestinal receptor expression and better calcium handling, broad population studies have shown mixed and modest effects that heavily depend on background diet and overall health.
Sources & further reading
Educational information only, last refreshed 9/8/2026. Not medical advice — these associations describe population statistics, not individual predictions.
Curious what your genotype is for rs11568825?
Upload a raw DNA file from 23andMe, AncestryDNA, MyHeritage, or FamilyTreeDNA and see this variant — plus thousands more — interpreted in your full report.
Get my report — $29Related variants in VDR
Variant in the promoter region (Cdx2 site) of the vitamin D receptor gene associated with altered intestinal calcium absorption and bone mineral density.
This variant in the Vitamin D receptor gene is associated with susceptibility to Type 1 Diabetes and autoimmune thyroid disease.
Promoter polymorphism (Cdx2) in the VDR gene associated with bone mineral density and vitamin D metabolism.
Common polymorphism (TaqI variant) in the vitamin D receptor affecting mRNA stability and bone mineral density.
Known as the TaqI polymorphism, this variant is located in the 3' UTR of the VDR gene and is associated with altered mRNA stability, influencing vitamin D signaling, cancer cachexia susceptibility, and gastric cancer risk.
Variant in the VDR promoter (Cdx-2 binding site) associated with bone mineral density and calcium absorption efficiency.